Evidence map›Paper›PMID 11390610›Full record

ArticleJournal of virology2001

Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein.

J M Johnson, C Nicot, J Fullen, V Ciminale, L Casareto, J C Mulloy, S Jacobson, G Franchini

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 125 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Complete Rescue of HTLV-1Pathogens (Basel, Switzerland) · 2024
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

J M JohnsonBasic Research Laboratory, National Cancer Institute, 41 Library Dr., Bethesda, MD 20892, USA.
C Nicot
J Fullen
V Ciminale
L Casareto
J C Mulloy
S Jacobson
G Franchini
Cancer Institute (WIA) · INNational Cancer Institute · MYNational Institute of Neurological Disorders and Stroke · USUniversity of Padua · IT

Funding

Involvement Of Human Viruses Associated With Chronic Neurologic DiseaseZIANS002817 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI JACOBSON, STEVEN · 2009 to 2025
$26.5M
Retrovirus Associated With Chronic Neurologic DiseaseZ01NS002817 · NINDS · NEUROLOGICAL DISORDERS AND STROKE · PI JACOBSON, STEVEN · 1990 to 2008
$4.0M
6 · The paper itself

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) establishes a persistent infection in the host despite a vigorous virus-specific immune response. Here we demonstrate that an HTLV-1-encoded protein, p12(I), resides in the endoplasmic reticulum (ER) and Golgi and physically binds to the free human major histocompatibility complex class I heavy chains (MHC-I-Hc) encoded by the HLA-A2, -B7, and -Cw4 alleles. As a result of this interaction, the newly synthesized MHC-I-Hc fails to associate with beta(2)-microglobulin and is retrotranslocated to the cytosol, where it is degraded by the proteasome complex. Targeting of the free MHC-I-Hc, and not the MHC-I-Hc-beta(2)-microglobulin complex, by p12(I) represents a novel mechanism of viral interference and disrupts the intracellular trafficking of MHC-I, which results in a significant decrease in surface levels of MHC-I on human T-cells. These findings suggest that the interaction of p12(I) with MHC-1-Hc may interfere with antigen presentation in vivo and facilitate escape of HTLV-1-infected cells from immune recognition.

Indexed as

Transcription Factorsbeta 2-MicroglobulinBiological TransportCysteine EndopeptidasesEndoplasmic ReticulumGolgi ApparatusHeLa CellsHistocompatibility Antigens Class IHLA-A2 AntigenHLA-B7 AntigenHLA-C AntigensHumansMultienzyme ComplexesOncogene Proteins, ViralProteasome Endopeptidase ComplexViral Regulatory and Accessory Proteinsbeta 2-MicroglobulinCysteine EndopeptidasesHistocompatibility Antigens Class IHLA-A2 AntigenHLA-B7 AntigenHLA-C*04 antigenHLA-C AntigensMultienzyme ComplexesOncogene Proteins, Viralp12I protein, Human T-lymphotropic virus 1Proteasome Endopeptidase ComplexTranscription FactorsViral Regulatory and Accessory Proteins

Identifiers

PMID11390610
PMCPMC114324
OpenAlexW2168298202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.